SCHEMBL23013405

SCHEMBL23013405

O=C(N[C@H]1N=C(c2ccccc2)c2cccc(F)c2NC1=O)c1c(-c2cccc(F)c2F)nn2cccnc12

nearest known ligand 0.44

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ CCKBR P32239 13/20 0.44
▸ CCKAR P32238 9/20 0.44
▸ NOTCH1 P46531 3/20 0.43
▸ RBPJ Q06330 2/20 0.43
▸ BDKRB1 P46663 1/20 0.40
▸ NOTCH3 Q9UM47 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29692144 1.00 CCKBR (0.44) CCKBRCCKARNOTCH1RBPJBDKRB1
SCHEMBL23023712 1.00 CCKBR (0.44) CCKBRCCKARNOTCH1RBPJBDKRB1
SCHEMBL29692200 0.95 CCKBR (0.45) CCKBRCCKARNOTCH1RBPJBDKRB1
SCHEMBL23013106 0.95 CCKBR (0.45) CCKBRCCKARNOTCH1RBPJBDKRB1
SCHEMBL29692236 0.94 CCKBR (0.46) CCKBRCCKARNOTCH1RBPJBDKRB1
SCHEMBL23013247 0.94 CCKBR (0.46) CCKBRCCKARNOTCH1RBPJBDKRB1
SCHEMBL29903324 0.93 CCKBR (0.43) CCKBRCCKARNOTCH1RBPJBDKRB1
SCHEMBL29692141 0.93 CCKBR (0.45) CCKBRCCKARNOTCH1RBPJBDKRB1
SCHEMBL28749173 0.93 CCKBR (0.45) CCKBRCCKARNOTCH1RBPJBDKRB1
SCHEMBL30286734 0.92 CCKBR (0.47) CCKBRCCKARNOTCH1RBPJ

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12227507-B2 Pharmaceutical compounds PFIZER INC. (US) 2025-02-18 — — US claimed
US-20220306639-A1 PHARMACEUTICAL COMPOUNDS PFIZER INC. 2022-09-29 — — US claimed
EP-4017856-A1 PHARMACEUTICAL COMPOUNDS Reviral Limited (GB) 2022-06-29 — — EP claimed
CN-114555604-A Pharmaceutical compounds 瑞威有限公司 2022-05-27 — — CN claimed
WO-2021032992-A1 PHARMACEUTICAL COMPOUNDS ReViral Limited (GB) 2021-02-25 — — WO claimed
US-12227507-B2 Pharmaceutical compounds PFIZER INC. (US) 2025-02-18 — — US disclosed
US-11634425-B2 Pharmaceutical compounds PFIZER INC. (US) 2023-04-25 — — US disclosed
US-11634425-B2 Pharmaceutical compounds PFIZER INC. (US) 2023-04-25 — — US disclosed
US-20220324873-A1 PHARMACEUTICAL COMPOUNDS PFIZER INC. 2022-10-13 — — US disclosed
US-20220306639-A1 PHARMACEUTICAL COMPOUNDS PFIZER INC. 2022-09-29 — — US disclosed
EP-4017856-A1 PHARMACEUTICAL COMPOUNDS Reviral Limited (GB) 2022-06-29 — — EP disclosed
WO-2021032992-A1 PHARMACEUTICAL COMPOUNDS ReViral Limited (GB) 2021-02-25 — — WO disclosed
WO-2021032992-A1 PHARMACEUTICAL COMPOUNDS ReViral Limited (GB) 2021-02-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12227507-B2 Pharmaceutical compounds CHRNA6, GABRA6, CHRNA7 CCKBR 488/4885CCKAR 199/4885NOTCH1 4608/4885
US-11634425-B2 Pharmaceutical compounds GABRA6, CHRNA6, CNR1 CCKBR 257/4885CCKAR 168/4885NOTCH1 4652/4885
US-20220306639-A1 PHARMACEUTICAL COMPOUNDS CHRNA6, GABRA6, CHRNA7 CCKBR 488/4885CCKAR 199/4885NOTCH1 4608/4885
US-20220324873-A1 PHARMACEUTICAL COMPOUNDS GABRA6, CNR1, CHRNA6 CCKBR 408/4885CCKAR 204/4885NOTCH1 4533/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback